The Company
The Company
Promore Pharma in Brief
Vision and Strategy
Market
Team
Board of Directors
Projects
Projects
Ropocamptide – Healing of Chronic Wounds
Publications
Investors
Investors
Promore Pharma on Nasdaq First North Growth Market
Certified Adviser
The Share
Shareholders
Warrant Programs
Share capital development
Analysts
Financial Reports
Press Releases
Prospectuses
Presentations and Events
Calendar
Subscribe
Corporate Governance
Corporate Governance
Corporate Governance
General Meeting
General Meetings
Nomination Committee
Nomination Committees
The Board of Directors
Board of Directors
The Management
Management
Remunerations and Remuneration Committee
Auditor and Audit Committee
Articles of Association
Certificate of Registration
Media
Media
Press Releases
Imagebank
Promore Pharma in Media
Subscribe
Contact
Contact
Office
Investors
Media
Svenska
The Company
Promore Pharma in Brief
Vision and Strategy
Market
Team
Board of Directors
Projects
Ropocamptide – Healing of Chronic Wounds
Publications
Investors
Promore Pharma on Nasdaq First North Growth Market
Certified Adviser
The Share
Shareholders
Warrant Programs
Share capital development
Analysts
Financial Reports
Press Releases
Prospectuses
Presentations and Events
Calendar
Subscribe
Corporate Governance
Corporate Governance
General Meeting
General Meetings
Nomination Committee
Nomination Committees
The Board of Directors
Board of Directors
The Management
Management
Remunerations and Remuneration Committee
Auditor and Audit Committee
Articles of Association
Certificate of Registration
Media
Press Releases
Imagebank
Promore Pharma in Media
Subscribe
Contact
Office
Investors
Media
Media
Press Releases
Imagebank
Promore Pharma in Media
Subscribe
Contact
Erik Magnusson
Chief Financial Officer (CFO)
+46 70 856 52 45
Press Releases
All press releases
Regulatory press releases
Non-regulatory press releases
2021
2023
2022
2020
2019
2018
2017
2016
2015
2013
All years
December 8, 2021
Promore Pharma granted US patent regarding treatment of chronic wounds
November 23, 2021
Interim report January – September 2021
November 19, 2021
Invitation to Conference Call regarding Promore Pharma’s Interim Report for the Third Quarter 2021
November 16, 2021
Nomination Committee Appointed for the Annual General Meeting 2022 in Promore Pharma
November 9, 2021
Promore Pharma receives permits to start a phase II clinical trial regarding scar prevention
October 25, 2021
Promore Pharma announces that scientific article has been published on clinical study results with ropocamptide for venous leg ulcers
September 13, 2021
Promore Pharma receives delivery of hyaluronic acid from Italian manufacturer Fidia
August 24, 2021
Interim report January – June 2021
August 17, 2021
Invitation to Conference Call regarding Promore Pharma’s Q2 Report 2021
July 20, 2021
The rights issue is registered and the trading in Paid Subscription Shares ceases
June 22, 2021
Outcome in Promore Pharma’s rights issue
June 2, 2021
Promore Pharma publishes prospectus
May 27, 2021
Promore Pharma informs about the last day of trading to receive subscription rights
May 27, 2021
Interim report January – March 2021
May 27, 2021
Report from an extra General Meeting of Promore Pharma AB held on 27 May 2021
May 27, 2021
Report from the Annual General Meeting of Promore Pharma AB held on 27 May 2021
May 26, 2021
Promore Pharma participates in “Småbolagsdagarna 2021”, an event organized by Aktiespararna
May 17, 2021
Invitation to Conference Call regarding Promore Pharma’s Q1 Report 2021
May 12, 2021
Promore Pharma is granted a US patent regarding skin scarring
May 10, 2021
Notice of Extraordinary General Meeting in Promore Pharma AB (publ)
May 7, 2021
Promore Pharma AB intends to carry out a fully secured rights issue in order to implement the new strategy
May 6, 2021
Promore Pharma’s Annual Report 2020 and AGM related Documents Published
April 28, 2021
Promore Pharma signs agreement on production of hyaluronic acid with Italian manufacturer Fidia
April 27, 2021
NOTICE OF ANNUAL GENERAL MEETING PROMORE PHARMA AB (PUBL)
March 31, 2021
Promore Pharma comments on media reports about ensereptide
March 31, 2021
Promore Pharma deregisters warrants
March 31, 2021
Promore Pharma updates its strategy and focuses on scar prevention
February 23, 2021
Year-end report 2020
February 16, 2021
Invitation to Presentation of Promore Pharma’s Year-end report for 2020
January 20, 2021
Promore Pharma changes Certified Adviser to Erik Penser Bank AB
